Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indivior Sets Out Next Steps As It Braces For Suboxone Rivals

Executive Summary

Indivior is exhausting all its options to try and stop the impending launch of US generic rivals to Suboxone from 19 February, including petitioning the country’s Supreme Court to intervene. But even if Dr Reddy’s and Alvogen do launch their versions next week, the originator is planning to combat them with an authorized generic.

You may also be interested in...

Mylan Is Latest Entrant On US Generic Suboxone

Mylan has joined Alvogen, Dr Reddy’s and Sandoz in the battle over US generic versions of Indivior’s Suboxone sublingual film. However, it is only marketing two of the four strengths offered by its rivals.

Alvogen and Dr Reddy’s US Suboxone Rivals Face Off Against Sandoz’ Authorized Generic

Alvogen and Dr Reddy’s have launched generic versions of Indivior’s Suboxone in the US, after the Supreme Court denied the originator’s attempt to further frustrate generic launches. But these two versions will compete with an authorized generic launched by Indivior through Sandoz.

Indivior Trading Update Reveals Hurdles Suboxone ANDA Filers Are Facing

Dr Reddy’s Laboratories is agonizingly close to resuming market activities for its generic Suboxone sublingual film product, but recently saw its case to have a mandate confirming the dismissal of a preliminary injunction turned down. In a market update, Suboxone manufacturer Indivior has outlined its plans to combat the imminent threat.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts